- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03052634
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
A Phase Ib Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Breast Cancer With HER2 Positive or HER2 Low Expression
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Harbin, China
- Affiliated Cancer Hospital of Harbin Medical University
-
Hebei, China
- The Fourth Hospital of Hebei Medical University
-
Nanjing, China
- Jiangsu Cancer Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Jilin
-
Changchun, Jilin, China
- The first bethune hospital of jilin unversity
-
-
Liaoning
-
Shenyang, Liaoning, China
- Liaoning Cancer Hospital & Institute
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Cancer hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntary signed informed consent;
- Female, aged between 18 to 70 years;
- ECOG performance status score of 0 or 1;
- Life expectancy greater than 12 weeks;
Patients with locally advanced or metastatic breast cancer diagnosed by histology or cytology, and:
- Core cohort: standard treatment is ineffective (the disease progresses or has no remission after treatment) or cannot tolerate standard treatment, or HER2 positive who cannot receive standard treatment (immunohistochemistry is 2+ and confirmed by fluorescence in situ hybridization [FISH] Positive, or immunohistochemical 3+) patients;
- Explorative cohort:standard treatment is ineffective (the disease progresses or has no remission after treatment) or cannot tolerate standard treatment, or had no optional standard treatment for HER2 immunohistochemistry 2+ with FISH negative or HER2 immunohistochemistry 1+ (FISH negative or untested). Subjects in the explorative cohort can provide HER2 detection of tumor primary or metastatic site specimens;
- Measurable lesion according to the RECIST 1.1;
- Adequate organ function:
(1)absolute neutrophil count(ANC) >= 1.5 x 10(9)/L; (2) platelets>=100*10(9)/L; (3)Total serum bilirubin <=1.5*ULN; (4)serum aspartate transaminase (AST)and serum alanine transaminase (ALT) <=2.5*ULN, or AST and ALT<=5*ULN with hepatic metastasis; (5) Serum creatinine clearance rate >= 45 mL/min; (6) INR<=1.5*ULN and APTT<=1.5*ULN; 8.Women of child-bearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices, complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 6 months after the last dose of study drug; 9.Left ventricular ejection fraction (LVEF) >= 50%.
Exclusion Criteria:
- Women who are pregnant (positive blood test before medication) or breastfeeding;
- Patients received anti-cancer therapy within 4 weeks before study drug treatment;, including chemotherapy, radiotherapy, surgery or hormone therapy, molecular targeted therapy (including trastuzumab etc.); Using Trastuzumab emtansine(T-DM1) or participating in the clinical trial on ADC drugs targeting HER2 and bispecific antibodies targeting HER2;
- The patient have third interstitial fluid (a large number of pleural effusion or ascites) which has clinical symptom or can not be controlled by drainage or other methods;
- Received Palliative radiation therapy for bone metastases within 2 weeks before study drug treatment;
- Toxicity of previous anti-tumor treatment has not recovered to CTCAE [version 4.0] 0-1, except for hair loss;
- Participated in other clinical trials within 4 weeks;
- Known hypersensitivity or delayed hypersensitivity to the some components of RC48-ADC or similar drugs;
- The active infection with clinical significance according to the researcher's judgment;
- Diagnosed with HBsAg or HBcAb positive and HBV DNA positive, or HCV Ab positive, or HIV Ab positive.
- Have a history of immunodeficiency, including a positive HIV test, or other acquired, congenital immunity Epidemic defects, or a history of organ transplantation;
- Uncontrolled systemic diseases such as diabetes, hypertension, Pulmonary fibrosis, acute lung disease, interstitial lung disease, etc.
- Congestive heart failure with grade 2 or higher (including grade 2) of the New York Institute of Cardiology (NYHA) of the United States in the history of diseases such as acute myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months prior to entry ;
- Insufficient adherence to participate in this clinical study;
- Patients who had received systemic steroid therapy for a long time(Patients who had received systemic steroid therapy for short time and stopped drug more than 2 weeks could be enrolled );
- Primary brain or metastatic tumor;
- Peripheral neuropathy with grade≥2;
- People with a history of mental illness that is difficult to control.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RC48-ADC 1.5 mg/kg (HER2 Positive)
|
15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks.
They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
|
Experimental: RC48-ADC 2.0 mg/kg (HER2 Positive)
|
15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks.
They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
|
Experimental: RC48-ADC 2.5 mg/kg (HER2 Positive)
|
15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks.
They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
|
Experimental: RC48-ADC 2.0 mg/kg (HER2 Low Expression)
|
45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks.
They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RP2D
Time Frame: Estimated 2 year
|
Recommended Phase II Dose
|
Estimated 2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Estimated 2 year
|
Maximum Observed Plasma Concentration
|
Estimated 2 year
|
AUC
Time Frame: Estimated 2 year
|
Area Under Curve
|
Estimated 2 year
|
Tmax
Time Frame: Estimated 2 year
|
Time for Cmax
|
Estimated 2 year
|
Overall response Rate (ORR)
Time Frame: Estimated 2 year
|
As per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 - to estimate the anti-tumor activity of RC48-ADC.
|
Estimated 2 year
|
Clinical Benefit Rate (CBR)
Time Frame: Estimated 2 year
|
Clinical Benefit Rate was defined as the percentage of patients with complete remission (CR) partial remission (PR) stable (SD) not less than 4 months.
|
Estimated 2 year
|
Progression Free Survival (PFS)
Time Frame: Estimated 2 year
|
Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
Estimated 2 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jianmin Fang, RemeGen Co., Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C003 CANCER
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Breast Cancer
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
Zhejiang Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingFemale Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
Royal Marsden NHS Foundation TrustPfizer; Hoffmann-La RocheRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast CancerUnited Kingdom
-
University Hospital TuebingenRecruitingAdvanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)Germany
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
National Center of Oncology, ArmeniaBRIU GmbHCompletedAdvanced Breast Cancer | Metastatic Breast CancerArmenia
Clinical Trials on RC48-ADC 1.5 mg/kg (HER2 Positive)
-
RemeGen Co., Ltd.Active, not recruitingBreast Neoplasms | Breast Diseases | HER2-positive Breast Cancer | Capecitabine | HER2 Positive Breast Carcinoma | HER2-positive Advanced Breast With Liver MetastasesChina
-
RemeGen Co., Ltd.Recruiting
-
PfizerTerminatedMultiple SclerosisUnited States
-
RemeGen Co., Ltd.CompletedGastric Cancer | HER2 Overexpressing Gastric CarcinomaChina
-
Bill & Melinda Gates Medical Research InstituteRecruiting
-
RemeGen Co., Ltd.RecruitingAdvanced Melanoma | Melanoma, Stage II | HER2-positiveChina
-
RemeGen Co., Ltd.Active, not recruitingBiliary Tract CancerChina
-
RemeGen Co., Ltd.Completed
-
RemeGen Co., Ltd.CompletedAdvanced Cancer | Urothelial CarcinomaChina
-
RemeGen Co., Ltd.RecruitingGynecological MalignancyChina